Palisade Bio (NASDAQ:PALI) Rating Reiterated by Maxim Group

Maxim Group restated their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $22.50 price target on the stock. Palisade Bio Price Performance Shares of Palisade Bio stock opened at $4.71 on Tuesday. Palisade Bio has a 1 […]

Related Keywords

United States , , Vanguard Group Inc , Virtu Financial , Renaissance Technologies , Maxim Group , Geode Capital Management , Palisade Bio Inc , Palisade Bio , Free Report , Get Free Report , Capital Management , Street Corp , Palisade Bio Daily , Nasdaq Pali , Upali , Medical , Reiterated Rating ,